Recognition and management of bipolar depression

Journal of Clinical Outcomes Management

Volumn 18, Issue 11, 2011, Pages 515-525

  Schroeder, Emily ^a   Gao, Yonglin ^a   Roberts, R Jeannie ^a   El Mallakh, Rif S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ARMODAFINIL; CARBAMAZEPINE; FLUOXETINE; GABAPENTIN; KETAMINE; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; MODAFINIL; OLANZAPINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SEROTONIN; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ATTENTION DEFICIT DISORDER; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COGNITIVE THERAPY; DRUG MEGADOSE; FAMILY COUNSELING; HUMAN; HUMAN RELATION; HYPOMANIA; JET LAG; LITERATURE; LOW DRUG DOSE; MANIA; NARCOLEPSY; PARKINSON DISEASE; PSYCHOEDUCATION; PSYCHOTHERAPY; RESTLESS LEGS SYNDROME; REVIEW; SLEEP APNEA SYNDROME; SOCIAL INTERACTION;

EID: 81855225325     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Calabrese JR, Hirschfeld RM, Reed M, et al. Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry 2003;64:425-32. (Pubitemid 36547287)
2. Judd LL, Schettler PJ, Solomon DA, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord 2008;108:49-58. (Pubitemid 351418013)
3. Goldberg JF, Harrow M. A 15-year prospective follow-up of bipolar affective disorders: comparisons with unipolar nonpsychotic depression. Bipolar Disord 2011;13:155-63.
4. Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005;62:1322-30. (Pubitemid 41746610)
5. Calabrese JR, Hirschfeld RM, Frye MA, et al. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry 2004;65:1499-504.
6. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7. (Pubitemid 34602935)
7. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-9. (Pubitemid 36307437)
8. Goldstein BI, Herrmann N, Shulman KI. Comorbidity in bipolar disorder among the elderly: results from an epidemiological community sample. Am J Psychiatry 2006;163:319-21. (Pubitemid 44480855)
9. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003;64:161-74. (Pubitemid 36268319)
10. Smith DJ, Ghaemi N. Is underdiagnosis the main pitfall when diagnosing bipolar disorder? Yes. BMJ 2010;340: c854.
11. Stewart C, El-Mallakh R. Is bipolar disorder overdiagnosed among patients with substance abuse? Bipolar Disorders 2007;9:646-8. (Pubitemid 47365633)
12. Goldberg JF, Garno JL, Callahan AM, et al. Overdiagnosis of bipolar disorder among substance use disorder in patients with mood instability. J Clin Psychiatry 2008;69:1751-7.
13. Ghaemi N, Sachs GS, Goodwin FK. What is to be done? Controversies in the diagnosis and treatment of manic-depressive illness. World J Biol Psychiatry 2000;1:65-74.
14. Mitchell PB, Goodwin GM, Johnson GF, et al. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord 2008;10(1 Pt 2):144-52.
15. Meyer TD, Fuhr K, Hautzinger M, et al. Recognizing mania in children and adolescents-age does not matter, but decreased need for sleep does. Compr Psychiatry 2011;52:132-8.
16. Fiedorowicz JG, Endicott J, Leon AC, et al. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 2011;168:40-8.
17. Benazzi F. A prediction rule for diagnosing hypomania. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:317-22.
18. Hirschfeld RM, Calabrese JR, Weissman MM, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-9. (Pubitemid 36182230)
19. Hirschfeld RM, Cass AR, Holt DC, et al. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract 2005;18:233-9. (Pubitemid 41663994)
20. Miller CJ, Klugman J, Berv DA, et al. Sensitivity and specificity of the Mood Disorder Questionnaire for detecting bipolar disorder. J Affect Disord 2004;81:167-171. (Pubitemid 39070092)
21. Correa R, Akiskal H, Gilmer W, et al. Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? J Affect Disord 2010;127(1-3):10-18.
22. Luddington NS, Mandadapu A, Husk M, et al. Clinical implications of genetic variation of the promoter region of the serotonin transporter. Prim Care Comp J Clin Psychiatry 2009;11:93-102.
23. Mansour HA, Talkowski ME, Wood J, et al. Serotonin gene polymorphisms and bipolar I disorder: Focus on the serotonin transporter. Ann Med 2005;37:590-602. (Pubitemid 41780147)
24. Thiruvengadam AP, Chandrasekaran K. Evaluating the validity of blood-based membrane potential changes for the identification of bipolar disorder I. J Affect Disord 2007;100(1-3):75-82. (Pubitemid 46818429)
25. Woodruff DB, El-Mallakh RS, Thiruvengadam AP. Validation of a diagnostic screening blood test for bipolar disorder. Ann Clin Psychiatry 2011. Forthcoming.
26. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-47. (Pubitemid 39201448)
27. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011;72:156-67.
28. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: A naturalistic study. J Clin Psychiatry 2000;61:804-8.
29. Ghaemi SN, Hsu DJ, Thase ME, et al. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv 2006;57:660-5.
30. Cascade EF, Reites J, Kalali AH, et al. Antidepressants in bipolar disorder. Psychiatry (Edgmont) 2007;4:56-8.
31. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad Med 2000;Spec No:1-104v
32. Hirschfeld RMA, Bowden CL, Gitlin M, et al. Amercian Psychiatric Association Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4 Suppl):1-50. (Pubitemid 34274969)
33. Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987;144:1403-11. (Pubitemid 18009530)
34. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group . J Clin Psychiatry 1999;60:79-88. (Pubitemid 29104383)
35. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-22. (Pubitemid 46658703)
36. El-Mallakh RS, Karippot A. Chronic depression in bipolar disorder. Am J Psychiatry 2006:163:1137-41.
37. Post RM, Leverich GS, Nolen WA, et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord 2003;5:396-406. (Pubitemid 38072242)
38. Nemeroff CB, Evans DL, Gyulai L, et al. A double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-12. (Pubitemid 32547620)
39. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88. Erratum in: Arch Gen Psychiatry 2004;61:176. (Pubitemid 37429647)
40. Brown E, Dunner DL, McElroy SL, et al. Olanzapine/ fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 2009;12:773-82.
41. Amsterdam J. Efficacy and safety of venlafaxine in treatment of bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:414-7. (Pubitemid 28462632)
42. Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Efficacy and safety of fluoxtine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1990;18:435-40.
43. El-Mallakh RS. Adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;357:615. (Pubitemid 47236293)
44. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder(STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010;71:372-80.
45. El-Mallakh RS, Ghaemi SN, Sagduyu K, et al., for the STEP-BD Investigators. Antidepressant-Associated Chronic Irritable Dysphoria (ACID) in STEP-BD Patients. J Affect Disord 2008;111(2-3):372-7.
46. Mundo E, Walker M, Cate T, et al. The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry 2001;58:539-44. (Pubitemid 32523733)
47. Rousseva A, Henry C, van den Bulke D, et al. Antidepressant- induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J 2003;3:101-4. (Pubitemid 36675710)
48. Masoliver E, Menoyo A, Perez V, et al. Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressantinduced mania in bipolar disorder. Psychiatric Genet 2006;16:25-9.
49. Young AH, McElroy SL, Bauer M, et al.; A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71:150-62.
50. Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166:476-88.
51. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacol 2008;33:2303-12.
52. Pfizer. Protocol A1281136. A six-week, randomized, double-blind, multicenter, fixed-flexible dose, placebocontrolled study evaluating the efficacy and safety of oral ziprasidone in outpatients with Bipolar I Depression. www.pfizermedicalinformation.com/content/pdfRedirect. jsp?http://www.clinicalstudyresults.org/documents/company- study-8815-0.pdf.
53. Pfizer. Protocol A1281139. A six-week, double-blind, multicenter, placebo-controlled study evaluating the efficacy and safety of flexible doses of oral ziprasidone in outpatients with a diagnosis of Bipolar I Depression. www.pfizermedicalinformation.com/content/pdfRedirect. jsp?http://www. clinicalstudyresults.org/documents/company- study-8843-0.pdf.
54. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20. Erratum in: J Clin Psychopharmacol 2009;29:38.
55. Sheehan DV, McElroy SL, Harnett-Sheehan K, et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord 2009;115:376-85.
56. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment- resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006;163:210-6. (Pubitemid 44480839)
57. Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010;13:305-20.
58. Altamura AC, Serati M, Buoli M, et al. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol 2011. [Epub ahead of print]
59. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009;194:4-9.
60. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432-41.
61. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000;61:841-50.
62. El-Mallakh RS. Lithium: actions and mechanisms. Washington, DC: American Psychiatric Press; 1996.
63. Frye MA, Yatham L, Ketter TA, et al. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebocontrolled bipolar I maintenance studies. Acta Psychiatr Scand 2009;120:10-13.
64. Frye MA, Denicoff KD, Bryan AL, et al. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry 1999;156 :1909-14.
65. Bond DJ, Lam RW, Yatham LN. Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 2010;124:228-34.
66. Muzina DJ, Gao K, Kemp DE, et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naive bipolar I or II depression: a double-blind, randomized, placebo- controlled trial. J Clin Psychiatry 2010. [Epub ahead of print]
67. Allen MH, Hirschfeld RM, Wozniak PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006;163:272-5. (Pubitemid 44480847)
68. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980;137:782-90. (Pubitemid 10085113)
69. Post RM, Ketter TA, Uhde T, et al. Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs 2007;21:47-71. (Pubitemid 46072350)
70. El-Mallakh RS, Salem MR, Chopra A, et al. A blinded, randomized comparison of carbamazepine immediate-release and extended release capsules in manic and depressed bipolar subjects. Ann Clin Psychiatry 2010;22:3-8.
71. Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002;51:253-60. (Pubitemid 34142637)
72. Maj J, Rogó Z, Skuza G, et al. The effect of repeated treatment with pramipexole on the central dopamine D3 system. J Neural Transm 2000;107:1369-79. (Pubitemid 32049933)
73. Wermuth L. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neur 1998;5:235-42. (Pubitemid 28256611)
74. Jama L, Hirvonen K, Partinen M, et al. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance. Sleep Med 2009;10:630-6.
75. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-6. (Pubitemid 38326114)
76. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60. (Pubitemid 38813406)
77. El-Mallakh RS, Penagaluri P, Kantamneni A, et al. Longterm use of pramipexole in bipolar depression: A naturalistic retrospective chart review. Psychiatric Quarterly 2010;81:207-13.
78. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-51. (Pubitemid 27368880)
79. Krystal AD, Harsh JR, Yang RR, et al. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. Clin Psychiatry 2010;71:32-40.
80. Rosenberg RP, Bogan RK, Tiller JM, et al. A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clin Proc 2010;85:630-8.
81. Gill M, Haerich P, Westcott K, et al. Cognitive performance following modafinil versus placebo in sleep-deprived emergency physicians: a double-blind randomized crossover study. Acad Emerg Med 2006;13:158-65. (Pubitemid 43155822)
82. Czeisler CA, Walsh JK, Wesnes KA, et al. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc 2009;84:958-72.
83. Hauck W, Adam P, Bobier C, et al. Use of large-scale chromatography in the preparation of armodafinil. Chirality 2008;20:896-9.
84. Beck P, Odle A, Wallace-Huitt T, et al. Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. Sleep 2008;31:1647-54.
85. 11C]raclopride. Biol Psychiatry 2010;68:964-70.
86. Ishizuka T, Murotani T, Yamatodani A. Modanifil activates the histaminergic system through the orexinergic neurons. Neurosci Lett 2010;483:193-6.
87. Frey MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164:1242-9. (Pubitemid 47292414)
88. Calabrese JR, Ketter TA, Youakim JM, et al. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, doubleblind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2010;71:1363-70.
89. El-Mallakh RS. An open study of methylphenidate in bipolar depression. Bipolar Dis 2010;2:56-9.
90. Findling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:1445-1453. (Pubitemid 351338965)
91. Zeni CP, Tramontina S, Ketzer CR, et al. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol 2009;19:553-61.
92. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793-802.
93. Lankenau SE, Bloom JJ, Shin C. Longitudinal trajectories of ketamine use among young injection drug users. Int J Drug Policy 2010;21:306-14.
94. Swartz, HA, Frank, E. Psychotherapy for bipolar depression: A phase-specific treatment strategy? Bipolar Disord 2001;3:11-22. (Pubitemid 32219844)
95. Van der Voort TG, Goossens PJ, Van Der Bijl JJ. Burden, coping and needs for support of caregivers for patients with a bipolar disorder: A systematic review. J Psychiatr Ment Health Nurs 2007;14:679-87.
96. Srivastava S, Bhatia M, Sharma V, et al. Health-related quality of life in bipolar disorder patients and their caregivers. Int J Men Health 2010;39:3-15.
97. Reinares M, Colom F, Sánchez-Moreno J, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord 2008;10:511-9. Erratum in: Bipolar Disord 2008;10:657. (Pubitemid 351619167)
98. Miklowitz DJ, George EL, Richards JA, et al. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003;60:904-12. (Pubitemid 37122310)
99. Perlick DA, Miklowitz DJ, Lopez N, et al. Family-focused treatment for caregivers of patients with bipolar disorder. Bipolar Disorders 2010;12:627-37.
100. Miklowitz DJ, Axelson DA, Birmaher B, et al. Familyfocused treatment for adolescents with bipolar disorder: results of a 2-year randomized trial. Arch Gen Psychiatry2008;65:1053-61.
101. Miklowitz DJ, Axelson DA, George EL, et al. Expressed emotion moderates the effects of family-focused treatment for bipolar adolescents. J Am Acad Child Adolesc Psychiatry 2009;48:643-51.
102. Madigan K, Egan P, Brennan D, et al. A randomised controlled trial of carer-focussed multi-family group psychoeducation in bipolar disorder. Eur Psychiatry 2011;Feb 18. [Epub ahead of print]
103. Reinares M, Colom F, Rosa AR, et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. J Affect Disord 2010;123(1-3):81-6.
104. Colom F, Vieta E, Sánchez-Moreno J, et al. Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels. Bipolar Disord 2005;7 Suppl 5:32-6. (Pubitemid 43013458)
105. D'Souza R, Piskulic D, Sundram S. A brief dyadic group based psychoeducation program improves relapse rates in recently remitted bipolar disorder: a pilot randomised controlled trial. J Affect Disord 2010;120(1-3):272-6.
106. Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60:402-7. (Pubitemid 36403001)
107. Colom F, Vieta E, Sánchez-Moreno J, et al. Psychoeducation for bipolar II disorder: an exploratory, 5-year outcome subanalysis. J Affect Disord 2009;112(1-3):30-5.
108. Scott J, Colom F, Popova E, et al. Long-term mental health resource utilization and cost of care following group psychoeducation or unstructured group support for bipolar disorders: a cost-benefit analysis. Clin Psychiatry 2009;70:378-86.
109. Frank E. Interpersonal and social rhythm therapy: A means of improving depression and preventing relapse in bipolar disorder. J ClinPsychol 2007;63:463-73. (Pubitemid 46750310)
110. Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005;62:996-1004. (Pubitemid 41248379)
111. da Costa R, Rangé B, Malagris L, et al. Cognitive-behavioral therapy for bipolar disorder. Expert Review of Neurotherapeutics 2010;10:1089-99.
112. Hollon S D, Ponniah, K. A review of empirically supported psychological therapies for mood disorders in adults. Depression Anxiety 2010;27:891-932.
113. Zaretsky AE, Segal ZV, Gemar M. Cognitive therapy for bipolar depression: A pilot study. Can J Psychiat 1999;44:491-4. (Pubitemid 29325654)
114. Zaretsky A, Lancee W, Miller C, et al. Is cognitive-behavioural therapy more effective than psychoeducation in bipolar disorder? Can J Psychiat 2008;53:441-8.
115. Gregory VL Jr. Cognitive-behavioral therapy for depression in bipolar disorder: a meta-analysis. J Evid Based Soc Work 2010;7:269-79.
116. Isasi A, Echeburúa E, Limiñana J, et al. How effective is a psychological intervention program for patients with refractory bipolar disorder? A randomized controlled trial. J Affect Disorders 2010;126(1-2):80-7.
117. Miklowitz DJ, Scott J. Psychosocial treatments for bipolar disorder: cost-effectiveness, mediating mechanisms, and future directions. Bipolar Disord 2009;11(Suppl 2):110-22.